Clinical trials: HIV Seronegativity
HIV Infections
Botswana Study of UC-781 Vaginal Microbicide
This study will test the safety, side effects, and acceptability of two strengths of UC-781 gel when used by women and men in Botswana for two weeks.
- Trial name
- NCT00385554
- Testing
- UC-781 carbomer gel, 0.1% and 0.25%
- Where
- 3 sites in United States, Botswana
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
Safety Study of UC-781 Vaginal Microbicide
This study will help determine whether UC-781 gel is safe when applied to the vagina twice daily for 14 days, and will assess whether women and men find the gel acceptable to use.
- Trial name
- NCT00446979
- Testing
- UC 781
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
The Women's HIV SeroIncidence Study (ISIS)
Approximately 30 percent of new HIV infections in the Unites States occur in women, with a disproportionate number occurring in women of color.
- Trial name
- NCT00995176
- Where
- 9 sites in United States
- Volunteers
- 2,099 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV Infections
Botswana TDF/FTC Oral HIV Prophylaxis Trial
This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV…
- Trial name
- TDF2 (NCT00448669)
- Testing
- Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
- Where
- 2 sites in United States, Botswana
- Volunteers
- 1,219 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months
To evaluate in healthy volunteers the safety and immune response to 200 mcg gp120 candidate vaccine in MF59 emulsion without MTP-PE at 0, 1 and 6 months.
- Trial name
- NCT00000749
- Testing
- rgp120/HIV-1 SF-2
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults
Investigators will examine the safety of and immune responses to two vaccines expressing synthetic HIV proteins: NYVAC-B (a poxvirus), and rAd5 (an adenovirus).
- Trial name
- NCT00961883
- Testing
- NYVAC-B, rAd5
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Opiate Dependence, HIV Infections
HIV Risk Reduction and Drug Abuse Treatment in Iran
A randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and HIV risk reduction counseling (DC-HIV) for heroin and opium addicts in Iran.
- Trial name
- NCT00398008
- Testing
- Buprenorphine/Subutex, Naltrexone, Drug counseling
- Where
- 2 sites in United States, Iran
- Sponsor
- Yale University
HIV Infections, Gonorrhea
Cellulose Sulfate (CS) Gel and HIV in Nigeria
This is a Phase 3, multi-center, randomized, placebo-controlled trial to determine the effectiveness and safety of the 6% cellulose sulfate (CS) vaginal gel for the prevention of HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydia Infections
- Trial name
- NCT00120770
- Testing
- Cellulose Sulfate Vaginal Gel (Microbicide)
- Where
- 2 sites in Nigeria
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
The purpose of the study is to determine the safety of and immune response to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
- Trial name
- NCT00125970
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
- Where
- 12 sites in United States, Brazil and 3 more
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV Infections
Positive Lifestyles Using Safety
Project PLUS tests an HIV risk reduction/adherence behavioral intervention with HIV-infected individuals in Connecticut prisons.
- Trial name
- Project PLUS (NCT00836290)
- Testing
- Pre-Release (Group 1), Post-release (Group 2)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Yale University
HIV Infections
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
To evaluate the safety and immunogenicity of ALVAC-HIV MN120TMG (vCP205) in comparison to ALVAC-RG rabies glycoprotein (vCP65) as a control when administered in HIV-1 negative volunteers.
- Trial name
- NCT00001055
- Testing
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
- Where
- 6 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable.
- Trial name
- NCT00073216
- Testing
- Clade B gag DNA/PLG and env DNA/PLG Microparticles, Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
A Study of Immune System Activity in Healthy Adults
The purpose of this study is to compare immune system activity in young people and older people who do not have HIV. This information will be compared to that of HIV patients in another study.
- Trial name
- NCT00014053
- Where
- 9 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
The purpose of this study is to determine the safety, tolerability, and immune response to the DNA HIV vaccine, PENNVAX-B alone, in combination with IL-12, or with 2 different doses of IL-15.
- Trial name
- NCT00528489
- Testing
- PennVax B, IL-12, IL-15
- Where
- 8 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Substance Use
Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women
This study will examine safer sex skills building (SSB), a targeted behavioral HIV prevention and risk reduction group intervention in two samples of pregnant drug abusing women.
- Trial name
- NCT00619320
- Testing
- Safer Sex Skills Building (SSB)
- Where
- 2 sites in United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
HIV Infections
Culturally-Tailored HIV Risk Reduction for African-American MSM
The purpose of this study to conduct a small randomized control trial to compare the relative effectiveness of a single-session of HIV testing and counseling risk reduction intervention (HCT-only) to an enhanced intervention that…
- Trial name
- Project ABLE (NCT00691561)
- Testing
- Project ABLE
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
HIV Infections, HIV Seronegativity
HIV Incidence and Participation Retention in Pune, India
The purpose of this study is to ensure that the HIV Prevention Trials Unit (HPTU) in Pune will be able to enroll and retain participants for 2 upcoming HPTN clinical trials.
- Trial name
- NCT00028119
- Where
- India
- Volunteers
- 1,070 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
Opiate Dependence, HIV Infections
Brief Introductory Therapy for Opioid Dependence
A randomized clinical trial to compare the efficacy of Behavioral Drug and HIV Risk Reduction Counseling (BDRC) and standard methadone drug counseling.
- Trial name
- NCT00406484
- Testing
- Standard drug counseling, BDRC
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Yale University
HIV Infections, Herpesvirus 2, Human
Male Circumcision for HIV Prevention in Rakai, Uganda
Circumcision in HIV unifected men may reduce the likelihood of becoming infected with HIV, reduce sexually transmitted infections (STIs) in men, not engender increases in sexual risk behaviors, and be acceptable to men as a…
- Conditions
- HIV Infections, Herpesvirus 2, Human, Syphilis, Genital Diseases, Male
- Trial name
- NCT00425984
- Testing
- Adult male circumcision
- Where
- Uganda
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
- Trial name
- NCT00955006
- Testing
- VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)